Yunnan Baiyao(000538.SZ)

Last Updated 00:00:00
longbridge loading
Company Encyclopedia
View More
name
Yunnan Baiyao
000538.SZ
Yunnan Baiyao Group Co.,Ltd engages in the sale of pharmaceuticals, medicinal materials, health and daily chemical products in China. The company offers health products; traditional Chinese medicine used for pain management and anti-inflammation, including the Yunnan Baiyao aerosol, Yunnan Baiyao ointment, and Yunnan Baiyao band-aid; generic drugs and natural specialty medicines in various areas, such as physical fitness, respiratory ailments, cardiovascular health, gynecology, pediatrics, and others; medical devices; tea products; and pharmaceutical supply chain service solutions. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.
2.805 T
000538.SZMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking4/215
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.69%B
    • Profit Margin12.53%B
    • Gross Margin30.63%C
  • Growth ScoreC
    • Revenue YoY4.61%C
    • Net Profit YoY5.50%C
    • Total Assets YoY4.06%C
    • Net Assets YoY3.37%C
  • Cash ScoreC
    • Cash Flow Margin89.71%C
    • OCF YoY4.61%C
  • Operating ScoreB
    • Turnover0.76B
  • Debt ScoreB
    • Gearing Ratio25.31%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

    Wallstreetcn·
    SH
    512290
    +0.21%
    SZ
    159929
    +0.24%
    SH
    600436
    -1.46%
    Wallstreetcn·
    SH
    512290
    +0.21%
    SZ
    159929
    +0.24%
    SH
    600436
    -1.46%

    "Artificial Intelligence + Healthcare" welcomes new policies, multiple listed companies are expected to benefit

    Wallstreetcn·
    SZ
    000538
    +0.04%
    SZ
    002614
    +1.46%
    SH
    688410
    -0.50%
    Wallstreetcn·
    SZ
    000538
    +0.04%
    SZ
    002614
    +1.46%
    SH
    688410
    -0.50%

    Yunnan Baiyao released its performance for the first three quarters, with a net profit attributable to the parent company of 4.777 billion yuan, an increase of 10.41%

    Zhitong·
    SZ
    000538
    +0.04%
    Zhitong·
    SZ
    000538
    +0.04%

    Yunnan Baiyao: Net profit in the third quarter was 1.144 billion yuan, a year-on-year increase of 0.55%

    Zhitong·
    SZ
    000538
    +0.04%
    Zhitong·
    SZ
    000538
    +0.04%

    The market value of the hundred billion is in jeopardy! After a 20% plunge in profits, how will "Chinese medicine Moutai" ZZPZH turn the tide?

    Wallstreetcn·
    SZ
    000538
    +0.04%
    HK
    03613
    +0.55%
    SH
    600436
    -1.46%
    Wallstreetcn·
    SZ
    000538
    +0.04%
    HK
    03613
    +0.55%
    SH
    600436
    -1.46%
    © 2026 Longbridge｜Disclaimer